Business Description
Johnson & Johnson
NAICS : 325412
SIC : 2834
Compare
Compare
Traded in other countries / regions
JNJ.ArgentinaJNJ.AustriaJNJB34.BrazilJNJ.ChileJNJ.GermanyJNJ_KZ.KazakhstanJNJ.MexicoJNJ.PeruJNJ.Switzerland0R34.UKJNJ.UkraineJNJ.USA IPO Date
1944-09-25Description
Johnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women's health. Geographically, just over half of total revenue is generated in the United States.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.59 | |||||
| Equity-to-Asset | 0.41 | |||||
| Debt-to-Equity | 0.52 | |||||
| Debt-to-EBITDA | 1.37 | |||||
| Interest Coverage | 85.88 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 4.43 | |||||
| Beneish M-Score | -2.47 | |||||
| WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 5.2 | |||||
| 3-Year EBITDA Growth Rate | 5.8 | |||||
| 3-Year EPS without NRI Growth Rate | 6.1 | |||||
| 3-Year FCF Growth Rate | -4.6 | |||||
| 3-Year Book Growth Rate | 9.2 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 3.64 | |||||
| Future 3-5Y Total Revenue Growth Rate | 2.61 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 49.45 | |||||
| 9-Day RSI | 44.45 | |||||
| 14-Day RSI | 40.8 | |||||
| 6-1 Month Momentum % | -6.45 | |||||
| 12-1 Month Momentum % | -11 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.99 | |||||
| Quick Ratio | 0.77 | |||||
| Cash Ratio | 0.42 | |||||
| Days Inventory | 133.78 | |||||
| Days Sales Outstanding | 60.79 | |||||
| Days Payable | 122.07 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 2.96 | |||||
| Dividend Payout Ratio | 0.66 | |||||
| 3-Year Dividend Growth Rate | 5.9 | |||||
| Forward Dividend Yield % | 2.96 | |||||
| 5-Year Yield-on-Cost % | 3.96 | |||||
| 3-Year Average Share Buyback Ratio | 0.2 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 67.26 | |||||
| Operating Margin % | 24.97 | |||||
| Net Margin % | 18.9 | |||||
| ROE % | 23.83 | |||||
| ROA % | 9.96 | |||||
| ROIC % | 15.31 | |||||
| ROC (Joel Greenblatt) % | 117.06 | |||||
| ROCE % | 16.52 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 22.65 | |||||
| Forward PE Ratio | 14.51 | |||||
| PE Ratio without NRI | 22.65 | |||||
| Shiller PE Ratio | 24.32 | |||||
| Price-to-Owner-Earnings | 25.35 | |||||
| PEG Ratio | 5.03 | |||||
| PS Ratio | 4.28 | |||||
| PB Ratio | 5.19 | |||||
| Price-to-Free-Cash-Flow | 23.65 | |||||
| Price-to-Operating-Cash-Flow | 19.17 | |||||
| EV-to-EBIT | 22.38 | |||||
| EV-to-Forward-EBIT | 15.94 | |||||
| EV-to-EBITDA | 17 | |||||
| EV-to-Forward-EBITDA | 14.12 | |||||
| EV-to-Revenue | 5.19 | |||||
| EV-to-Forward-Revenue | 5.04 | |||||
| EV-to-FCF | 28.65 | |||||
| Price-to-Projected-FCF | 1.59 | |||||
| Price-to-DCF (Earnings Based) | 1.81 | |||||
| Price-to-DCF (FCF Based) | 1.88 | |||||
| Price-to-Median-PS-Value | 0.93 | |||||
| Earnings Yield (Greenblatt) % | 4.47 | |||||
| Forward Rate of Return (Yacktman) % | 8.65 |
How Johnson & Johnson (JNJ) Makes Its Money
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NYSE:JNJ
Peter Lynch Chart
Performance
Dividend
Log
Annualized Return %
Total Annual Return %
Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 94,943 | ||
| EPS (TTM) ($) | 6.74 | ||
| Beta | 0.43 | ||
| Volatility % | 16.62 | ||
| 14-Day RSI | 40.8 | ||
| 14-Day ATR ($) | 2.27975 | ||
| 20-Day SMA ($) | 153.187 | ||
| 12-1 Month Momentum % | -11 | ||
| 52-Week Range ($) | 150.11 - 186.69 | ||
| Shares Outstanding (Mil) | 3,119.84 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Johnson & Johnson Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||
Johnson & Johnson Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Johnson & Johnson Frequently Asked Questions
What is Johnson & Johnson(JNJ)'s stock price today?
The current price of JNJ is $152.65. The 52 week high of JNJ is $186.69 and 52 week low is $150.11.
When is next earnings date of Johnson & Johnson(JNJ)?
The next earnings date of Johnson & Johnson(JNJ) is 2023-04-18.
Does Johnson & Johnson(JNJ) pay dividends? If so, how much?
The Dividend Yield %  of Johnson & Johnson(JNJ) is 2.96% (As of Today), Highest Dividend Payout Ratio of Johnson & Johnson(JNJ) was 7.06. The lowest was 0.48. And the median was 0.58. The  Forward Dividend Yield % of Johnson & Johnson(JNJ) is 2.96%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
